Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments

被引:8
|
作者
Katic, Alain
Dirks, Bryan [1 ]
Babcock, Thomas [2 ]
Scheckner, Brian [2 ]
Adeyi, Ben [3 ]
Richards, Cynthia [1 ]
Findling, Robert L. [4 ]
机构
[1] Shire Dev LLC, Clin Dev & Innovat, Wayne, PA USA
[2] Shire Dev LLC, Global Med Affairs, Wayne, PA USA
[3] Shire Dev LLC, Biostat & Stat Programming Dept, Wayne, PA USA
[4] Johns Hopkins Univ, Johns Hopkins Med & Kennedy Krieger Inst, Div Child & Adolescent Psychiat, Baltimore, MD USA
关键词
DEFICIT HYPERACTIVITY; EXPRESSION;
D O I
10.1089/cap.2012.0104
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: The purpose of this study was to assess lisdexamfetamine dimesylate (LDX) treatment effects based on baseline emotional control dysfunction in children with attention-deficit/hyperactivity disorder (ADHD) categorized with or without impairments of executive function (EF) emotional control. Methods: Post-hoc analyses of a 7 week, open-label LDX study in children with ADHD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision [DSM-IV-TR] defined) and impairments in EF control of emotional response. At baseline, participants were dichotomized by Behavior Rating Inventory of EF (BRIEF) emotional control domain T-scores of >= 65 (with impairment) or <65 (without impairment). ADHD Rating Scale-IV (ADHD-RS-IV), BRIEF Global Executive Composite and emotional control domain, Expression and Emotion Scale for Children (EESC) scores, Pearson correlations for BRIEF versus ADHD-RS-IV and EESC, and Clinical Global Impressions scores were assessed at baseline and end of study (week 7)/early termination (EOS/ET) by baseline category of BRIEF emotional control impairment. Safety assessments included treatment-emergent adverse events (TEAEs). Results: At baseline and EOS/ET, respectively, 53.0% and 20.7% met criteria for emotional control impairment. Participants with and without emotional control impairments had similar ADHD-RS-IV change scores. Mean (SD) change from baseline for those with and without emotional control impairments were -20.8 (12.89) and -14.6 (11.25) for BRIEF global scores and -16.0 (13.19) and -5.0 (9.48) for BRIEF emotional control domain scores. Participants with emotional control impairments had greater mean EESC total score changes. BRIEF emotional control domain and all ADHD-RS-IV scores indicated moderate correlations between change scores (all p < 0.0001). Overall, 84.9% of participants had TEAEs (mostly mild-to-moderate in severity); 3.8% discontinued because of TEAEs. Conclusions: The proportion of children with behavioral impairments in EF control of emotional response decreased during LDX treatment. ADHD symptoms improved in both groups. The moderate correlations between EF behaviors and ADHD symptoms suggest there may be utility in evaluating behavioral domains beyond core ADHD symptoms.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 50 条
  • [1] Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
    Childress, Ann C.
    Findling, Robert L.
    Wu, James
    Kollins, Scott H.
    Wang, Yi
    Martin, Patrick
    Robertson, Brigitte
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2020, 30 (03) : 128 - 136
  • [2] Lisdexamfetamine Dimesylate In Attention-Deficit Hyperactivity Disorder in Adults
    Weber, Juliane
    Siddiqui, M. Asif A.
    CNS DRUGS, 2009, 23 (05) : 419 - 425
  • [3] Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents
    Mattos, Paulo
    REVISTA DE PSIQUIATRIA CLINICA, 2014, 41 (02): : 34 - 39
  • [4] Weight-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
    Lecendreux, Michel
    Zuddas, Alessandro
    Banaschewski, Tobias
    Soutullo, Cesar
    Bloomfield, Ralph
    Hodgkins, Paul
    Gasior, Maria
    Coghill, David
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S223 - S223
  • [5] An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder
    Wigal, Sharon B.
    Raja, Pooja
    Shukla, Ankita
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 137 - 145
  • [6] EFFECT OF LISDEXAMFETAMINE DIMESYLATE ON FUNCTIONAL IMPAIRMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
    Soutullo, C. A.
    Banaschewski, T.
    Lecendreux, M. L.
    Bloomfield, R.
    Hodgkins, P.
    Coghill, D. R.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [7] The first European studies of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
    Coghill, David
    Banaschewski, Tobias
    Lecendreux, Michel
    Soutullo, Cesar
    Johnson, Mats
    Zuddas, Alessandro
    Anderson, Colleen
    Civil, Richard
    Dauphin, Matthew
    Higgins, Nicholas
    Lyne, Andrew
    Gasior, Maria
    Squires, Liza
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S125 - S125
  • [8] Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
    Wigal, Timothy
    Brams, Matthew
    Gasior, Maria
    Gao, Joseph
    Giblin, John
    POSTGRADUATE MEDICINE, 2011, 123 (02) : 169 - 176
  • [9] The first European studies of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
    Coghill, D. R.
    Banaschewski, T.
    Lecendreux, M.
    Soutullo, C.
    Johnson, M.
    Zuddas, A.
    Anderson, C.
    Civil, R.
    Dauphin, M.
    Lyne, A.
    Gasior, M.
    Squires, L. A.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [10] Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
    Lenard A Adler
    David Goodman
    Richard Weisler
    Mohamed Hamdani
    Thomas Roth
    Behavioral and Brain Functions, 5